Boston Scientific (BSX) Earnings Analysis
Boston Scientific (BSX) next reports earnings on 2026-07-29, consensus EPS 0.828 USD. Last quarter (2026-04-22) it beat with EPS 0.8 USD vs 0.788 USD est (+1.5%). It has beaten estimates in 6/6 recent quarters (100%). Trailing P/E 17.90.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does BSX next report earnings?
| Next earnings date | 2026-07-29 |
|---|---|
| Consensus EPS estimate | 0.828 USD |
| Revenue estimate | 5.37B |
BSX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-22 | 0.8 USD | 0.788 USD | +1.5% | Beat |
| 2026-02-04 | 0.8 USD | 0.781 USD | +2.4% | Beat |
| 2025-10-22 | 0.75 USD | 0.714 USD | +5% | Beat |
| 2025-07-23 | 0.75 USD | 0.725 USD | +3.4% | Beat |
| 2025-02-05 | 0.7 USD | 0.657 USD | +6.5% | Beat |
| 2024-07-24 | 0.62 USD | 0.583 USD | +6.3% | Beat |
Beat rate: 6/6 (100%) over reported quarters with consensus data.
BSX valuation and analyst view
| Trailing P/E | 17.90 |
|---|---|
| Trailing EPS | 2.393 USD |
| Price / book | 2.47 |
| Dividend yield | 0.00% |
| Market cap | 63.73B |
| Analyst consensus | Buy (39 buy / 5 hold / 0 sell) |
| Avg price target | 68.72 USD |
Related research pages
Frequently asked questions
When is Boston Scientific (BSX)'s next earnings date?
Boston Scientific is next scheduled to report on 2026-07-29, with a consensus EPS estimate of 0.828 USD and revenue estimate of 5.37B.
Did BSX beat earnings last quarter?
In its 2026-04-22 report, BSX posted EPS of 0.8 USD versus a 0.788 USD estimate — a beat of 1.5%.
What is BSX's earnings track record?
Over the last 6 reported quarters with consensus data, BSX beat estimates 6 times (100%).
What is BSX's current P/E ratio and EPS?
BSX trades at a trailing P/E of 17.90 on trailing EPS of 2.392753720789279 USD.
What do analysts rate BSX?
Analyst consensus is "Buy" across 44 ratings (1 strong buy, 38 buy, 5 hold, 0 sell, 0 strong sell). Average 12-month price target: 68.72 USD.